Literature DB >> 10580104

Loss of heterozygosity in tumor cells requires re-evaluation: the data are biased by the size-dependent differential sensitivity of allele detection.

J Liu1, V I Zabarovska, E Braga, A Alimov, G Klein, E R Zabarovsky.   

Abstract

Normal tissue contamination of tumors may eclipse the detection of loss of heterozygosity (LOH) by microsatellite analysis and may also hamper isolation of tumor suppressor genes. To test the potential impact of this problem, we prepared artificial mixtures of mouse-human microcell hybrid lines that carried different alleles of the same chromosome 3 marker. After performing an allele titration assay, we found a consistent difference between the LOH of a high molecular weight (H) allele and the LOH of a low molecular weight (L) allele of the same CA repeat marker. It follows that normal tissue admixtures will be less of a problem when LOH affects a H allele than with a L allele. Random screening of 100 papers published between 1994 and 1999 revealed that the loss of a L allele was recorded at about half the frequency (52%) of loss of a H allele. To avoid this bias, we have developed rules for the evaluation of LOH data. We suggest that the loss of a L allele should be given more weight than the loss of a H allele in LOH studies using microsatellite markers.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10580104     DOI: 10.1016/s0014-5793(99)01523-9

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  8 in total

1.  Loss of heterozygosity studies revisited: prior quantification of the amplifiable DNA content of archival samples improves efficiency and reliability.

Authors:  Kathryn Farrand; Lydija Jovanovic; Brett Delahunt; Bryan McIver; Ian D Hay; Norman L Eberhardt; Stefan K G Grebe
Journal:  J Mol Diagn       Date:  2002-08       Impact factor: 5.568

2.  Preferential allelic deletion of RBSP3, LIMD1 and CDC25A in head and neck squamous cell carcinoma: Implication in cancer screening and early detection.

Authors:  Shreya Sarkar; Chinmay Kumar Panda
Journal:  Cancer Biol Ther       Date:  2018-04-13       Impact factor: 4.742

3.  The candidate tumor suppressor gene, RASSF1A, from human chromosome 3p21.3 is involved in kidney tumorigenesis.

Authors:  K Dreijerink; E Braga; I Kuzmin; L Geil; F M Duh; D Angeloni; B Zbar; M I Lerman; E J Stanbridge; J D Minna; A Protopopov; J Li; V Kashuba; G Klein; E R Zabarovsky
Journal:  Proc Natl Acad Sci U S A       Date:  2001-06-05       Impact factor: 11.205

4.  Diverse tumorigenic pathways in ovarian serous carcinoma.

Authors:  Gad Singer; Robert J Kurman; Hsueh-Wei Chang; Sarah K R Cho; Ie-Ming Shih
Journal:  Am J Pathol       Date:  2002-04       Impact factor: 4.307

5.  Nuclear BAP1 loss is common in intrahepatic cholangiocarcinoma and a subtype of hepatocellular carcinoma but rare in pancreatic ductal adenocarcinoma.

Authors:  Asmaa Mosbeh; Khalil Halfawy; Wael S Abdel-Mageed; Dina Sweed; Mohamed H Abdel Rahman
Journal:  Cancer Genet       Date:  2018-04-09

6.  Molecular genetic analysis of placental site trophoblastic tumors and epithelioid trophoblastic tumors confirms their trophoblastic origin.

Authors:  Robert J Oldt; Robert J Kurman; Ie-Ming Shih
Journal:  Am J Pathol       Date:  2002-09       Impact factor: 4.307

7.  Application of array CGH on archival formalin-fixed paraffin-embedded tissues including small numbers of microdissected cells.

Authors:  Nicola A Johnson; Rifat A Hamoudi; Koichi Ichimura; Lu Liu; Danita M Pearson; V Peter Collins; Ming-Qing Du
Journal:  Lab Invest       Date:  2006-06-05       Impact factor: 5.662

8.  Somatic deletion of the NF1 gene in a neurofibromatosis type 1-associated malignant melanoma demonstrated by digital PCR.

Authors:  Albert Rübben; Birke Bausch; Arjen Nikkels
Journal:  Mol Cancer       Date:  2006-09-10       Impact factor: 27.401

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.